This is a working overview of dihexa, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-24. Anything still debated is marked as such rather than presented as settled.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized research form. |
| Solubility | Soluble in DMSO; limited in water | Depends on purity and salt form. |
| Storage temperature | -20 °C or lower | Desiccated and protected from light. |
| Analytical method | RP-HPLC and LC-MS | Common for purity and identity. |
| Regulatory status | Research chemical in many countries | Not widely approved as a medicine. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Caesium-137 has a number of practical uses. In small amounts, it is used to calibrate radiation-detection equipment. In medicine, it is used in radiation therapy. In industry, it is used in flow meters, thickness gauges, moisture-density gauges (for density readings, with americium-241/beryllium providing the moisture reading), and in borehole logging devices. Caesium-137 is not widely used for industrial radiography because it is hard to obtain a very high specific activity material with a well defined (and small) shape, as caesium from used nuclear fuel contains stable caesium-133 and also long-lived caesium-135. Isotope separation is too costly compared to cheaper alternatives. Also, the higher specific activity caesium sources tend to be made from highly soluble caesium chloride (CsCl); as a result, if a radiography source were to be damaged, the risk of radioactive contamination is high. It is possible to make water-insoluble caesium sources (with ferrocyanides, for example) but their specific activity will be lower. Other chemically inert caesium compounds include caesium-aluminosilicate-glasses akin to the natural mineral pollucite. The latter has been used in demonstrations of chemically stable water-insoluble forms of nuclear waste for disposal in deep geological repositories. A large emitting volume will harm the image quality in radiography.
== References == Hansard Indexes for 1993–2000, "Legislature of Western Australia" "No.32 (Special)". Western Australia Government Gazette. 16 February 1993. p. 1993:1287–1289. "No.116 (Special)". Western Australia Government Gazette. 25 August 1993. p. 1993:4599. "No.8 (Special)". Western Australia Government Gazette. 25 January 1994. p. 1994:278–279. "No.18 (Special)". Western Australia Government Gazette. 10 February 1995. p. 1995:477–478. "No.176 (Special)". Western Australia Government Gazette. 21 December 1995. p. 1995:6163–6164. "No.5 (Special)". Western Australia Government Gazette. 9 January 1997. p. 1997:99–100. Phillips, Harry; Black, David (June 1996). "Australian Political Chronicle: July–December 1995". Australian Journal of Politics and History. 42 (2): 271. ISSN 0004-9522.
When Burger King Corporation began franchising in 1959, it used a regional model where franchisees purchased the right to open stores within a geographic region. These franchise agreements granted BKC very little oversight control of its franchisees and resulted in issues of product quality control, store image and design, and operational procedures. During the 1970s, structural deficiencies in Burger King's franchise system became increasingly problematic for Pillsbury. A major example was the relationship between Burger King and Louisiana-based franchisee Chart House, Burger King's largest franchisee group at the time with over 350 locations in the United States. The company's owners, William and James Trotter, made several moves to take over or acquire Burger King during the 1970s, all of which were spurned by Pillsbury. After the failed attempts to acquire the company, the relationship between Chart House and Burger King soured and eventually devolved into a lawsuit. Chart House eventually spun off its Burger King operations in the early 1980s into a holding company called DiversiFoods which, in turn, was acquired by Pillsbury in 1984 and absorbed into Burger King's operations. As part of the franchising reorganization segment of Operation Phoenix, Donald N. Smith initiated a restructuring of future franchising agreements in 1978.
Sources: en.wikipedia.org
=== Epidemiological and medical === Bogden JD, Kemp FW, Buse M, et al. (January 1981). "Composition of tobaccos from countries with high and low incidences of lung cancer. I. Selenium, polonium-210, Alternaria, tar, and nicotine". J. Natl. Cancer Inst. 66 (1): 27–31. doi:10.1093/jnci/66.1.27. PMID 6935462. Hecht SS (July 1999). "Tobacco smoke carcinogens and lung cancer". J. Natl. Cancer Inst. 91 (14): 1194–210. doi:10.1093/jnci/91.14.1194. PMID 10413421. Ernster, Virginia, et al. "Women and tobacco: moving from policy to action." Bulletin of the World Health Organization 78 (2000): 891–901. online Frieden, Thomas R. et al. The Health Consequences of Smoking: 50 Years of Progress: A Report of the Surgeon General (2014) online Kluger, Richard. Ashes to Ashes: America's Hundred-Year Cigarette War, the Public Health, and the Unabashed Triumph of Philip Morris (Vintage, 1997). excerpt Matuszko J (November 2006). "Tobacco Products Processing Detailed Study" (PDF). www.epa.gov. U.S. Environmental Protection Agency. Archived (PDF) from the original on October 9, 2022. Retrieved March 29, 2017. Oreskes, Naomi, and Erik M. Conway. Merchants of doubt: How a handful of scientists obscured the truth on issues from tobacco smoke to global warming (Bloomsbury Publishing USA, 2011). Slade, John. "The tobacco epidemic: lessons from history." Journal of psychoactive drugs 21.3 (1989): 281–291. online Warner, Kenneth E. 1986. Selling Smoke: Cigarette Advertising and Public Health (American Public Health Association, 1986). online
== History == Vicine was initially isolated in 1870 from the seeds of Vicia sativa by a method of extraction with sulfuric acid and subsequent precipitation with mercury sulfate (HgSO4). Later vicine was also found in other Vicia species, namely Vicia faba, beet juice and peas. The chemical structure of the compound was built gradually. First the glycosidic nature of the compound was recognized in 1896. The same year the aglycone of vicine, divicine, was isolated. In the beginning of the 20th century the pyrimidine structure was recognized. Despite these initial successes, the correct formula of vicine was determined only in 1953 and it is 2,4-diamino-6-oxypyrimidine-5-(β-D-glucopyranoside).
== Manufacturing == Semaglutide has been approved in biologically and chemically synthesized forms. Approval of the original brand-name versions (such as Ozempic) was based on a biologic (recombinant DNA) production process using a genetically-modified yeast (Saccharomyces cerevisiae) to produce a precursor to semaglutide, and subsequent chemical processes (protein purification) to create the active ingredient. Approval of generic versions has instead been based on fully chemical syntheses that yield the same semaglutide molecule from the assembly of amino acids. Compounded drug versions of semaglutide have been created and made widely available, albeit without approval.
Collision-induced dissociation (CID), also known as collisionally activated dissociation (CAD), is a mass spectrometry technique to induce fragmentation of selected ions in the gas phase. The selected ions (typically molecular ions or protonated molecules) are usually accelerated by applying an electrical potential to increase the ion kinetic energy and then allowed to collide with neutral molecules (often helium, nitrogen, or argon). In the collision, some of the kinetic energy is converted into internal energy which results in bond breakage and the fragmentation of the molecular ion into smaller fragments. These fragment ions can then be analyzed by tandem mass spectrometry. CID and the fragment ions produced by CID are used for several purposes. Partial or complete structural determination can be achieved. In some cases, identity can be established based on previous knowledge without determining structure. Another use is in simply achieving more sensitive and specific detection. By detecting a unique fragment ion, the precursor ion can be detected in the presence of other ions of the same m/z value (mass-to-charge ratio), reducing the background and increasing the limit of detection.
Sources: en.wikipedia.org
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.
Mass spectrometry is commonly used to confirm molecular mass, while RP-HPLC estimates purity. These methods can be combined with amino acid analysis or NMR for further structural confirmation. A certificate of analysis alone does not guarantee independent verification.
Legality depends on the country and the intended use. In many places it is not approved as a drug and may be regulated as a research chemical. Buyers should check local laws and institutional policies before obtaining it.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.